Disodium combretastatin A-4 3-O-Phosphate

康普瑞丁磷酸二钠

Report date: 2026/03/30 17:02:26

Base Information

Drug NameDisodium combretastatin A-4 3-O-Phosphate
Drug Alias NameCombretastatin A-4 phosphate - Mateon Therapeutics康布斯汀康普立停Combretastatin-A4 phosphate福他布林 +[24] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCadherin 5 inhibitorsTubulin inhibitorsVascular disrupting agents (VDA)
TargetsCadherin 5Tubulin
Therapy Area/IndicationsSolid tumoursPolypoidal choroidal vasculopathyChoroidal Neovascularization +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaUnited States +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesOncotelic Therapeutics IncShanghai Ecust Biomedicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Ecust Biomedicine Co LtdPku Healthcare Corp Ltd
Inactive CompaniesOncotelic Therapeutics IncJohns Hopkins UniversityNational Cancer Institute +[5] 
Active IndicationsSolid tumours
Inactive IndicationsPolypoidal choroidal vasculopathyChoroidal NeovascularizationMacular Degeneration +[12] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG